Basket cover image
15 handpicked stocks

Cinema Revival: AMC's Next Feature

This group of stocks has been carefully selected by our professional analysts to capture the potential rebound in the movie theater industry. From theater chains like AMC to content creators and premium experience providers, these companies are positioned to benefit as audiences return to the big screen.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 14

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

AMC

AMC Entertainment Holdings, Inc.

AMC

Current price

$2.86

The catalyst for the theme, benefiting directly from the analyst upgrade, improved debt structure, and positive box office trends.

IMAX

IMAX Corporation

IMAX

Current price

$25.66

A resurgence in blockbuster movie attendance directly boosts demand for IMAX's premium, high-margin viewing experiences.

DIS

The Walt Disney Company

DIS

Current price

$116.27

A major film studio powerhouse (including Marvel, Pixar, and Star Wars) that relies on strong box office performance for its tentpole releases.

About This Group of Stocks

1

Our Expert Thinking

A major analyst upgrade for AMC Entertainment signals a potential turning point for the entire movie industry. This collection includes companies across the cinematic value chain positioned to benefit from improved attendance, a strong film slate, and renewed consumer confidence in the theatrical experience.

2

What You Need to Know

This theme represents a tactical investment opportunity focused on the recovery of the traditional cinema experience. The group includes theater operators, film studios, content creators, and companies providing premium viewing experiences - all connected to the big screen comeback.

3

Why These Stocks

These companies were handpicked to provide exposure to key players throughout the entertainment ecosystem. Each stands to benefit from increased cinema attendance, from theater chains directly serving moviegoers to the studios creating blockbuster content and the technology enhancing the viewing experience.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+30.57%

Group Performance Snapshot

30.57%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 30.57% over the next year.

14 of 15

Stocks Rated Buy by Analysts

14 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🎬

The Big Screen Comeback

Movie theaters are experiencing a resurgence as audiences return to cinemas for blockbuster experiences that streaming can't match. These stocks are positioned to capitalize on this renewed enthusiasm.

📈

Analyst Spotlight

A significant upgrade for market leader AMC has signaled a potential turning point for the entire sector. When the industry leader rises, it often lifts related companies throughout the entertainment ecosystem.

💰

Beyond Just Tickets

This group captures value across the entire cinema experience - from theater chains to content creators, premium formats, and even in-theater advertising. It's a comprehensive play on the theatrical revival.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.